On September 23, 2015 Clovis Oncology (NASDAQ:CLVS) reported that three oral presentations and four scientific posters highlighting updated results from clinical studies of the company’s two compounds in advanced clinical development are being presented at the 2015 European Cancer Congress (ECC), which will take place Sept. 25-29 in Vienna, Austria (Press release, Clovis Oncology, SEP 23, 2015, View Source;p=RssLanding&cat=news&id=2089808 [SID:1234507525]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to have the opportunity to share significant clinical progress across our product pipeline at ECC this year," said Patrick J. Mahaffy, CEO and President of Clovis Oncology. "Some key highlights include updated results from our rucaparib studies in the treatment of advanced ovarian cancer, including ARIEL2, for which we intend to file our initial regulatory submissions in the US in mid-2016."

Rucaparib, the Company’s oral, potent, small molecule inhibitor of PARP1 and PARP2 being developed for the treatment of ovarian cancer, specifically in patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA such as high genomic LOH (also referred to as "BRCA-like"), is the subject of two oral presentations and two posters:

Abstract #2700 – Final results of ARIEL2 (Part 1): a Phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis

R Kristeleit
Tuesday, Sept. 29, 9-9:15am CEST
Room: Hall A2

Abstract #2701 – Quantification of genomic loss of heterzygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib

A Oza
Tuesday, Sept. 29, 9:15-9:30am CEST
Room: Hall A2

Poster # P409 – A phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation

R Shapira-Frommer
Monday, Sept. 28, 2015, 9:15-11:15am CEST
Room: Hall C

Rociletinib, the Company’s oral, potent, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) under investigation for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC), is the subject of one oral and three posters presentations:

Abstract #3009 – Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement

A Varga
Monday, Sept. 28, 10:10-10:25am CEST
Room: Strauss

Poster # P356 – Rociletinib treatment and outcomes in non-small cell lung cancer (NSCLC) patients with negative central testing for T790M

B Soloman
Sunday, Sept. 27, 9:15-11:15am CEST
Room: Hall C

Poster # P356 – Efficacy of rociletinib (CO-1686) in EGFR-mutant non-small cell lung cancer (NSCLC) patients assessed with a plasma EGFR test

S Gadgeel
Sunday, Sept. 27, 9:15-11:15am CEST
Room: Hall C

Poster # P357 – Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial

JC Soria
Sunday, Sept. 27, 9:15-11:15am CEST
Room: Hall C

About Rucaparib

Rucaparib is an oral, potent small molecule inhibitor of PARP1 and PARP2 being developed for the treatment of ovarian cancer, specifically in patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA, such as high genomic LOH, which is commonly referred to as "BRCA-like." Rucaparib was granted Breakthrough Therapy designation by the U.S. FDA in April 2015.

About Rociletinib

Rociletinib is an oral, potent, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) under investigation for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). Rociletinib targets the activating mutations of EGFR (L858R and Del19), while also inhibiting the dominant acquired resistance mutation, T790M, which develops in approximately 60 percent of patients treated with first- and second-generation EGFR inhibitors, while sparing wild-type, or "normal" EGFR at anticipated therapeutic doses. Rociletinib was granted Breakthrough Therapy designation by the U.S. FDA in May 2014.